Claire C. J. Dekkers

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

David Z.I. Cherney, Claire C. J. Dekkers, Sean J. Barbour et al. · The Lancet Diabetes & Endocrinology · 2020 · 262 citations · Full text

Renal Function, Renal Disease, Crossover Trial +7

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers

Claire C. J. Dekkers, S. Petrykiv, Gozewijn D. Laverman et al. · Diabetes Obesity and Metabolism · 2018 · 250 citations · Full text

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

Claire C. J. Dekkers, C. David Sjöström, Peter J. Greasley et al. · Diabetes Obesity and Metabolism · 2019 · 102 citations · Full text

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Claire C. J. Dekkers, David C. Wheeler, C. David Sjöström et al. · Nephrology Dialysis Transplantation · 2017 · 100 citations · Full text

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors

Mie K. Eickhoff, Claire C. J. Dekkers, Bart J. Kramers et al. · Journal of Clinical Medicine · 2019 · 92 citations · Full text